The FDA in February accepted a New Drug Application under priority review for Incyte Corp.’s ruxolitinib cream for the treatment of atopic dermatitis. Meanwhile, there are currently more than 10 agents in Phase III trials for this indication. Among the medications that are on the market, Sanofi and Regeneron’s Dupixent (dupilumab) and Pfizer Inc.’s Eucrisa (crisaborole) are competing for preferred status after topical corticosteroids, topical calcineurin inhibitors and phototherapy. Most medications are covered under the pharmacy benefit, with the exception of Dupixent. More than half of payer pharmacy benefit formularies do not require step therapy or prior authorization for atopic dermatitis medications.
NOTE: Under the pharmacy benefit, the total covered lives under commercial, health exchange, Medicare and Medicaid formularies are 170.0 million, 11.7 million, 47.8 million and 69.8 million, respectively. Under the medical benefit, the total covered lives under commercial, health exchange, Medicare and Medicaid formularies are 168.4 million, 11.7 million, 49.5 million and 69.8 million, respectively.
SOURCE: Managed Markets Insight & Technology, LLC database as of May 2021.